ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 41 | October 25, 1985

Download PDF Visit The Full Archive

Related Articles

Bepler To Lead Karmanos Cancer Institute

January 29, 2010

“Recalcitrant” Cancers? Committee Rewrite Of Pancreatic Bill Raises New Questions

September 14, 2012

ESA Risk Mitigation Strategy Requires Training, Patient Consent, Documentation

February 19, 2010

Lifestyle Changes Common After Cancer Diagnosis

August 26, 2005

In Brief: NCI Future Budget Planning Now In Open; One Or Two comp Centers In 12-18 Months

May 28, 1976

In Brief: NCI Recieves Two Proposals For Antineoplaston Trials, None For Children; Stubble Elected To NAS

June 19, 1992